Literature DB >> 12210388

Conduction slowing in diabetic distal polyneuropathy.

David N Herrmann1, Michele L Ferguson, Eric L Logigian.   

Abstract

The pathophysiologic significance of motor conduction slowing observed in diabetic distal symmetrical polyneuropathy (DSP) remains controversial. We have used multiple linear regression analysis of compound muscle action potential (CMAP) amplitude vs. motor conduction velocity (CV) and distal latency (DL) in 57 patients with diabetic DSP and 34 patients with amyotrophic lateral sclerosis (ALS) to determine whether motor conduction slowing in diabetic DSP is due mainly to loss of large axons as in ALS or whether there is an additional demyelinative component. We found amplitude-dependent slowing of CV and DL in both diabetic DSP and ALS in the upper and lower extremities, consistent with a loss of large myelinated fibers. However, in diabetic DSP, there was also significant amplitude-independent slowing in intermediate but not distal nerve segments, supportive of an additional demyelinative component. CMAP amplitude vs. CV and DL regression analyses using ALS as a control group for relatively pure axon loss may provide pathophysiologic information about motor nerves in other neuropathic disorders. Copyright 2002 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12210388     DOI: 10.1002/mus.10204

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  8 in total

1.  Cutaneous Aβ-Non-nociceptive, but Not C-Nociceptive, Dorsal Root Ganglion Neurons Exhibit Spontaneous Activity in the Streptozotocin Rat Model of Painful Diabetic Neuropathy in vivo.

Authors:  Laiche Djouhri; Asad Zeidan; Seham A Abd El-Aleem; Trevor Smith
Journal:  Front Neurosci       Date:  2020-05-25       Impact factor: 4.677

Review 2.  Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy.

Authors:  Moaz Mojaddidi; Cristian Quattrini; Mitra Tavakoli; Rayaz A Malik
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

Review 3.  Pharmacotherapy of painful diabetic neuropathy.

Authors:  Richard Barbano; Stephanie Hart-Gouleau; Janet Pennella-Vaughan; Robert H Dworkin
Journal:  Curr Pain Headache Rep       Date:  2003-06

4.  Conduction slowing in diabetic sensorimotor polyneuropathy.

Authors:  Samantha K Dunnigan; Hamid Ebadi; Ari Breiner; Hans D Katzberg; Leif E Lovblom; Bruce A Perkins; Vera Bril
Journal:  Diabetes Care       Date:  2013-09-11       Impact factor: 19.112

5.  Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination.

Authors:  Alon Abraham; Majed Alabdali; Mohammad Qrimli; Hana Albulaihe; Ari Breiner; Carolina Barnett; Hans D Katzberg; Leif E Lovblom; Bruce A Perkins; Vera Bril
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

6.  Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes.

Authors:  Ari Breiner; Carolina Barnett Tapia; Leif Erik Lovblom; Bruce A Perkins; Hans D Katzberg; Vera Bril
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-07-10

7.  Corneal confocal microscopy differentiates inflammatory from diabetic neuropathy.

Authors:  Michael Fleischer; Inn Lee; Friedrich Erdlenbruch; Lena Hinrichs; Ioannis N Petropoulos; Rayaz A Malik; Hans-Peter Hartung; Bernd C Kieseier; Christoph Kleinschnitz; Mark Stettner
Journal:  J Neuroinflammation       Date:  2021-04-08       Impact factor: 8.322

8.  Peripheral neuropathy predicts nuclear gene defect in patients with mitochondrial ophthalmoplegia.

Authors:  Alejandro Horga; Robert D S Pitceathly; Julian C Blake; Catherine E Woodward; Pedro Zapater; Carl Fratter; Ese E Mudanohwo; Gordon T Plant; Henry Houlden; Mary G Sweeney; Michael G Hanna; Mary M Reilly
Journal:  Brain       Date:  2014-10-03       Impact factor: 13.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.